Table 2.
Univariate and multivariate analyses of PFS and OS.
| PFS | OS | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | ||||||||||
| N | HR [95% CI] | p-Value | N | HR [95% CI] | p-Value | N | HR [95% CI] | p-Value | N | HR [95% CI] | p-Value | ||
| Age at inclusion #, years | 91 | 1.02 (1.002–1.04) | 0.0334 | 91 | 1.02 (1.00–1.04) |
0.0378 | 91 | 1.01 (0.99–1.04) | 0.286 | ||||
| Metastasis to diagnosis interval #, years | 91 | 1.02 (0.98–1.06) | 0.34 | 91 | 1.03 (0.99–1.08) | 0.173 | |||||||
| Pathological type of primary tumor | lobular vs. ductal | 81 | 1.24 (0.53–2.86) | 0.621 | 81 | 1.60 (0.57–4.49) | 0.371 | ||||||
| Pathological grade of primary | 2 vs. 1 | 74 | 0.74 (0.28–1.97) | 0.453 | 74 | 0.64 (0.19–2.18) | 0.533 | ||||||
| 3 vs. 1 | 0.59 (0.23–1.55) | 0.53 (0.16–1.80) | |||||||||||
| Molecular subtype of primary | HER2pos | 90 | 1.47 (0.74–2.91) | 0.151 | 90 | 1.50 (0.67–3.39) | 0.262 | ||||||
| TN | 1.99 (0.96–4.12) | 1.98 (0.85–4.64) | |||||||||||
| Molecular subtype of metastasis | HER2pos | 87 | 0.87 (0.43–1.76) | 0.866 | 87 | 1.26 (0.58–2.73) | 0.694 | ||||||
| TN | 1.05 (0.67–1.67) | 1.25 (0.73–2.14) | |||||||||||
| Bone metastasis | yes vs. no | 91 | 0.89 (0.57–1.38) | 0.591 | 91 | 1.04 (0.62–1.74) | 0.892 | ||||||
| Liver metastasis | yes vs. no | 91 | 0.81 (0.52–1.25) | 0.335 | 91 | 1.01 (0.62–1.66) | 0.958 | ||||||
| Lung-pleural metastasis | yes vs. no | 91 | 1.09 (0.72–1.66) | 0.679 | 91 | 1.06 (0.65–1.71) | 0.817 | ||||||
| Brain-meningeal metastasis | yes vs. no | 91 | 1.42 (0.73–2.75) | 0.304 | 91 | 3.15 (1.58–6.28) | 0.00115 | 91 | 2.74 (1.37–5.48) |
0.00454 | |||
| Lymph node metastasis | yes vs. no | 91 | 1.06 (0.68–1.65) | 0.784 | 91 | 1.14 (0.68–1.91) | 0.607 | ||||||
| Skin metastasis | yes vs. no | 91 | 1.02 (0.60–1.74) | 0.942 | 91 | 1.43 (0.81–2.51) | 0.219 | ||||||
| Peritoneum metastasis | yes vs. no | 91 | 1.20 (0.62–2.32) | 0.597 | 91 | 1.50 (0.71–3.16) | 0.287 | ||||||
| Other metastatic site | yes vs. no | 91 | 0.95 (0.59–1.53) | 0.845 | 91 | 1.34 (0.80–2.23) | 0.269 | ||||||
| Number of metastasic sites at inclusion #, N | 91 | 1.00 (0.86–1.15) | 0.948 | 91 | 1.12 (0.96–1.30) | 0.158 | |||||||
| Number of previous lines of systemic therapy at inclusion #, N | 91 | 1.10 (1.01–1.21) | 0.0348 | 91 | 1.06 (0.96–1.16) |
0.23193 | 91 | 1.11 (1.01–1.23) | 0.0396 | 91 | 1.09 (0.98–1.20) |
0.10355 | |
| all atypical circulating cells | positive vs. negative | 91 | 1.37 (0.89–2.10) | 0.158 | 91 | 1.50 (0.91–2.49) | 0.115 | ||||||
| s-aCTC | positive vs. negative | 91 | 1.51 (0.99–2.29) | 0.056 | 91 | 1.51 (0.93–2.45) | 0.093 | ||||||
| CTM | positive vs. negative | 91 | 1.16 (0.77–1.76) | 0.478 | 91 | 1.35 (0.83–2.20) | 0.221 | ||||||
| g-aCTC | positive vs. negative | 91 | 1.94 (1.25–3.01) | 0.00298 | 91 | 1.87 (1.19–2.95) |
0.00661 | 91 | 2.46 (1.47–4.12) | 0.000584 | 91 | 2.23 (1.31–3.78) |
0.00298 |
#: variables tested as continuous values. Statistically significant p-value are in bold.